Activation and expansion of T-cells using an engineered multivalent signaling platform
AssigneeThe Trustees of the University of Pennsylvania
InventorsCarl June, James Riley, Marcela Maus, Anna Thomas
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells using an engineered multivalent signaling platform. Compositions of cells activated and expanded by the methods herein are further provided.
Claims84
An engineered multivalent signaling platform (EMSP) for use in stimulating and/or activating T cells comprising an EMSP that expresses or displays on its surface one or more agents that ligate a cell surface moiety of at least a portion of T-cells and stimulates said T-cells.
A method for activating or stimulating a population of T-cells by cell surface moiety ligation, comprising:
- a. providing a population of cells wherein at least a portion thereof comprises T-cells;
- b. contacting said population of cells with an EMSP, said EMSP having on its surface one or more agents that ligate a cell surface moiety of at least a portion of said T-cells and activates or stimulates said T-cells.
A method for maintaining T-cell repertoire comprising providing a population of cells having T-cells present therein, exposing said T-cells to an EMSP for a time sufficient to induce activation and subsequently expanding said T-cells.
A method for maintaining the viability of T-cells during culture, comprising contacting said T-cells with EMSP.
A method for decreasing apoptosis of a population of CD8+ T-cells, comprising stimulating said cells with EMSP, said EMSP having on its surface at least one primary stimulatory agent and at least one co-stimulatory agent.
A method for expanding a population of T-cells by cell surface moiety ligation, comprising:
- a. providing a population of cells wherein at least a portion thereof comprises T-cells;
- b. contacting said population of cells with an EMSP, said EMSP having on its surface one or more agents that ligate a cell surface moiety of at least a portion of said T-cells and activates or stimulates said T-cells;
- and
- c. culturing said T-cells under conditions and time sufficient to induce cell division, wherein said contacting and/or said culturing occurs in the absence of exogenously added cytokines.
A method for expanding a population of T-cells by cell surface moiety ligation, comprising:
- a. providing a population of cells wherein at least a portion thereof comprises T-cells;
- b. contacting said population of cells with an EMSP, said EMSP having on its surface one or more agents that ligate a cell surface moiety of at least a portion of said T-cells and activates or stimulates said T-cells;
- and
- c. culturing said T-cells under conditions and time sufficient to induce cell division.
A method of immunotherapy comprising administering an EMSP to a subject in need thereof, thereby stimulating a population of T-cells within the subject to expand.
A method of enhancing reactivity to an antigen comprising administering an EMSP to a subject in need thereof concurrently, prior to or following inoculation of the subject with an antigen of interest, thereby stimulating a population of antigen specific T-cells within the subject to expand.
A method for breaking immune tolerance comprising administering an EMSP to a subject either systemically or locally at a site of interest.
A method for increasing uptake of an exogenously added nucleic acid molecule in T-cells, comprising contacting said T-cells with an EMSP and contacting said T-cells with said nucleic acid molecule thereby, said contacting of EMSP with said T-cells rendering cells more amenable to uptake of nucleic acid.
A method of activating antigen specific T-cells, comprising contacting a population of T-cells an antigen and an EMSP under conditions and for time sufficient to induce activation of T-cells specific to said antigen.
Dependencies are inferred from the claim text.